Laura B. Goddard

Array ( [id] => 18195506 [patent_doc_number] => 20230049025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => ENGINEERED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 17/759222 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596090 [patent_doc_number] => 20230270881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => ONCOGENIC TRIM37 IS A TARGETABLE EPIGENETIC DRIVER OF METASTASIS AND LINKS CHEMORESISTANCE AND METASTATIC FATE IN TRIPLE-NEGATIVE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/794432 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17794432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854967 [patent_doc_number] => 20210155712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => TREATMENT AND PREVENTION OF CANCER USING HER3 ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/153705 [patent_app_country] => US [patent_app_date] => 2021-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18195475 [patent_doc_number] => 20230048994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => RECOMBINANT AAV PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/793196 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -98 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18195475 [patent_doc_number] => 20230048994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => RECOMBINANT AAV PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/793196 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -98 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170435 [patent_doc_number] => 20210324105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => BISPECIFIC ANTIBODIES AGAINST HER2 [patent_app_type] => utility [patent_app_number] => 17/149019 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18311007 [patent_doc_number] => 20230114907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => RT-PCR DETECTION METHOD AND KIT FOR NOVEL CORONAVIRUS [patent_app_type] => utility [patent_app_number] => 17/905662 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18311007 [patent_doc_number] => 20230114907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => RT-PCR DETECTION METHOD AND KIT FOR NOVEL CORONAVIRUS [patent_app_type] => utility [patent_app_number] => 17/905662 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739637 [patent_doc_number] => 20230348599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => METHODS FOR TREATING GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 17/786917 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18196930 [patent_doc_number] => 20230050449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/785590 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692885 [patent_doc_number] => 20250011430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => ANTI-B7H3 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/003996 [patent_app_country] => US [patent_app_date] => 2020-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964217 [patent_doc_number] => 11897968 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Anti-MerTK antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/118921 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 44 [patent_no_of_words] => 69884 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168559 [patent_doc_number] => 20230035169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGF-Beta [patent_app_type] => utility [patent_app_number] => 17/784617 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185263 [patent_doc_number] => 20210332148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => ANTIGEN-BINDING POLYPEPTIDES DIRECTED AGAINST CD38 [patent_app_type] => utility [patent_app_number] => 17/119073 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18141747 [patent_doc_number] => 20230015590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT [patent_app_type] => utility [patent_app_number] => 17/782415 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18180870 [patent_doc_number] => 20230041599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => USE OF MMP INHIBITION [patent_app_type] => utility [patent_app_number] => 17/781902 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18288933 [patent_doc_number] => 11617790 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-04 [patent_title] => Method for treating cancer using artificial adjuvant cell (aAVC) [patent_app_type] => utility [patent_app_number] => 17/312363 [patent_app_country] => US [patent_app_date] => 2020-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 13295 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853524 [patent_doc_number] => 20210154269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => COMBINATION THERAPIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/105353 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17105353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16856119 [patent_doc_number] => 20210156864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => Diagnostic and Therapeutic Biomarkers in Human Cancers and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 16/953581 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686834 [patent_doc_number] => 20210069309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => VACCINES AGAINST AN ONCOGENIC ISOFORM OF ESR1 AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/953211 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953211 [rel_patent_id] =>[rel_patent_doc_number] =>)